Back to News
Latest MHRA Drug Safety Update - February 2018
Posted on 20 Feb 2018
The latest MHRA Drug Safety Update, February 2018
This month article features are:
- advice about misoprostol vaginal delivery system (Mysodelle) following a routine review, which highlighted reports of uterine tachysystole, some of which did not respond to tocolytic treatment (page 2). Monitor patients closely and remove the vaginal delivery system immediately if there are excessive or prolonged uterine contractions, if there is concern for mother or baby, or at the onset of labour.
- read amended contraception advice for male patients taking mycophenolate medicines to prevent transplant rejection (page 3). As a precautionary measure, it is now recommended that either male patients or their female partner use reliable contraception during treatment with mycophenolate medicines and for at least 90 days after stopping (it was previously advised that both men receiving treatment and their female partners should use contraception to prevent pregnancy). Female patients of childbearing potential receiving mycophenolate medicines should always use contraception.
- update you as to the status of gadolinium-containing contrast agents after our previous article in the December 2017 issue of Drug Safety Update. Omniscan and intravenous Magnevist are no longer authorised for use and a product recall of existing unexpired stock is underway (page 5).